泼尼松与高剂量地塞米松在新诊断成人原发性免疫性血小板减少症中的随机试验
该随机试验比较泼尼松(PDN)与高剂量地塞米松(HD-DXM)在新诊断未治疗成人原发性免疫性血小板减少症(pITP)中的疗效。113例患者随机分组,Arm A接受PDN 1 mg/kg/天(第0-28天),Arm B接受HD-DXM 40 mg/天×4天,每14天重复,连续3个疗程。初始总反应率Arm B较高(93.88% vs 78.57%,P=0.0284),但持久反应率Arm A较高(80.65% vs 55.56%,P=0.0292)。
要点
- HD-DXM组初始总反应率93.88%高于PDN组78.57%(P=0.0284)。
- 12个月持续反应率PDN组80.65%高于HD-DXM组55.56%(P=0.0292)。
- 两组耐受性良好,中位随访44.4个月,48个月总生存率100%。
核心结论
- PDN与脉冲HD-DXM耐受性良好,HD-DXM可获得有效初始反应但持久性不及PDN。
研究设计与样本
- 随机试验,纳入新诊断未治疗pITP患者(年龄≥18且≤80岁,血小板计数≤20或>20但<50×10^9/L,出血评分≥8),113例随机分两组。
主要发现
- 可评估患者初始总反应(CR+PR+MR):Arm A 44/56(78.57%) vs Arm B 46/49(93.88%),P=0.0284。
- 最终总反应(初始反应后第180天):Arm A 26/43(60.47%) vs Arm B 23/39(58.97%),P=0.8907。
- 持续总反应(初始反应后12个月):Arm A 25/31(80.65%) vs Arm B 20/36(55.56%),P=0.0292。
- 发生7例复发,中位随访44.4个月,48个月总生存率100%,自第180天起48个月无病生存率81.11%。
关键数值与推荐
- Arm A:PDN 1 mg/kg/天,第0至28天。
- Arm B:HD-DXM 40 mg/天×4天,每14天一次,连续3个疗程。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A debate exists regarding which type of corticosteroids (standard-dose prednisone [PDN] or high-dose dexamethasone [HD-DXM]) is the best first-line treatment for adult patients with newly diagnosed untreated primary immune thrombocytopenia (pITP). An ad hoc study compared PDN with HD-DXM in newly diagnosed untreated patients with pITP (aged ≥18 but ≤80 years, platelet count of ≤20 or >20 but <50 × 109/L, and bleeding score of ≥8). Patients were randomised to receive PDN 1 mg/kg per day from days 0 to 28 (Arm A) or HD-DXM 40 mg per day for 4 days, every 14 days, for 3 consecutive courses (Arm B). Fifty-nine of 113 patients (52.2%) were randomized to Arm A and 54 of 113 (47.8%) to Arm B. In evaluable patients, total initial responses (complete response [CR], partial response [PR], minimal response [MR]) were 44 of 56 (78.57%) in Arm A and 46 of 49 (93.88%) in Arm B at days 42 and 46, respectively (P = 0.0284). Total final responses (at day 180 from initial response) were 26 of 43 (60.47%) in Arm A and 23 of 39 (58.97%) in Arm B (P = 0.8907). Total persistent responses (at 12 months from initial response) were 25 of 31 (80.65%) in Arm A and 20 of 36 (55.56%) in Arm B (P = 0.0292). Seven relapses occurred. Median follow-up was 44.4 months. Overall survival was 100% at 48 months, overall disease-free survival was 81.11% at 48 months from day 180. PDN and pulsed HD-DXM were well tolerated; HD-DXM allows effective initial responses but less long lasting than PDN. This trial was registered at www.clinicaltrials.gov as #NCT00657410.
引用
- Mazzucconi MG, Rodeghiero F, Avvisati G, et al. Prednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia: a randomized trial. Blood Adv. 2024. PMID: 38231017. doi:10.1182/bloodadvances.2023010975
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。